VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31

VERACYTE, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$43.80+0.68 (+1.58%)

Close on Oct 19, 2026

Market cap: $3.59B
P/E (TTM): 31.3
Dividend yield: –

Dividends

Veracyte has not reported a dividend

No dividend per share appears in Veracyte's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Veracyte's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VCYT.

Revenue growth17.3% · median 20.6%

Gross margin71.7% · median 65.0%

Operating margin18.8% · median -23.4%

Net margin20.4% · median -15.7%

Company	Revenue	Growth
GH	$1.18B	+42.7%
VCYT	$561.90M	+17.3%
CDNA	$458.09M	+34.4%
CSTL	$357.28M	+3.2%
FLGT	$323.93M	+6.8%
BNR	–	–

Company

Next earnings (est.): Nov 3, 2026, during market hours
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 755
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1384101

Advertisement
300 × 250